Related Experiment Videos
[Clinical and molecular genetics of hypertrophic cardiomyopathy]
Insights
Genetic mutations in sarcomeric proteins cause hypertrophic cardiomyopathy. Understanding these genetic causes aids diagnosis and may lead to future gene therapy for this heart muscle disease.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Sarcomere Biology
Context:
- Hypertrophic cardiomyopathy (HCM) is increasingly recognized as a disease of the cardiac sarcomere.
- Genetic mutations in sarcomeric protein-coding genes are the primary cause of HCM.
- Recent molecular genetics advancements have identified seven key genes associated with HCM.
Purpose:
- To review the genetic basis of hypertrophic cardiomyopathy.
- To explore the link between specific gene mutations and clinical outcomes.
- To discuss the implications of genetic findings for diagnosis and future therapies.
Summary:
- Mutations in seven genes encoding beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains, and troponin I cause hypertrophic cardiomyopathy.
- These mutations impact critical protein functions within the sarcomere, the heart muscle's contractile unit.
- The specific mutation influences disease severity, with some linked to malignant prognoses and sudden cardiac death, while others have a more favorable outlook.
Impact:
- Molecular genetics is transforming hypertrophic cardiomyopathy management, influencing diagnostic criteria.
- Identifying mutation carriers allows for personalized risk assessment and clinical strategies.
- Future directions include establishing routine genetic diagnostics and developing targeted gene therapies for HCM.
Abstract:
Recent developments in molecular genetics have allowed to identify mutations in seven genes coding the beta myosin heavy chain, troponin T, alpha tropomyosin, myosin binding protein C, essential and regulatory myosin light chains and troponin I causing hypertrophic cardiomyopathy. These mutations affect critical, evolutionary conserved nucleotides of these genes and influence vital functions of the encoded proteins. As all seven genes encodes sarcomeric proteins in the heart muscle, hypertrophic cardiomyopathy is regarded these days as a disease of the sarcomer. Recent data indicate that some mutations are associated with "malignant" clinical picture, with rapidly developing, severe symptoms of the disease and increased risk of sudden cardiac death while other mutations bear a more favourable prognosis. Apart of the disease causing mutation other factors, including disease modifier genes, are likely to make an impact on the clinical appearance of hypertrophic cardiomyopathy. The knowledge provided by molecular genetics influences the clinical management of the disease even today and based on the investigation of mutation carrying patients new diagnostic criteria was proposed for hypertrophic cardiomyopathy. The challenge for the future is the establishment of routine genetic diagnostics and the development of possible gene therapy.